ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 35 filers reported holding ASCENDIS PHARMA A/S in Q2 2017. The put-call ratio across all filers is - and the average weighting 1.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $13,805,000 | +11.1% | 133,691 | 0.0% | 36.44% | -19.2% |
| Q2 2022 | $12,428,000 | -20.8% | 133,691 | 0.0% | 45.08% | -5.7% |
| Q1 2022 | $15,690,000 | -12.8% | 133,691 | 0.0% | 47.81% | +5.0% |
| Q4 2021 | $17,985,000 | +828.5% | 133,691 | +860.3% | 45.53% | +4092.7% |
| Q4 2019 | $1,937,000 | -90.1% | 13,922 | -93.2% | 1.09% | -85.5% |
| Q3 2019 | $19,658,000 | -16.4% | 204,088 | 0.0% | 7.51% | -2.6% |
| Q2 2019 | $23,501,000 | -2.2% | 204,088 | 0.0% | 7.71% | +23.3% |
| Q1 2019 | $24,021,000 | +87.9% | 204,088 | 0.0% | 6.25% | +48.9% |
| Q4 2018 | $12,786,000 | -5.8% | 204,088 | +6.5% | 4.20% | +40.2% |
| Q3 2018 | $13,576,000 | +6.5% | 191,588 | 0.0% | 3.00% | +9.1% |
| Q2 2018 | $12,744,000 | -35.5% | 191,588 | -36.6% | 2.74% | -36.3% |
| Q1 2018 | $19,751,000 | +46.6% | 302,009 | -10.2% | 4.30% | +13.9% |
| Q4 2017 | $13,471,000 | +30.3% | 336,264 | +17.9% | 3.78% | +32.8% |
| Q3 2017 | $10,336,000 | +1561.7% | 285,143 | +1173.0% | 2.85% | +1302.5% |
| Q2 2017 | $622,000 | -77.8% | 22,400 | -77.6% | 0.20% | -81.1% |
| Q1 2017 | $2,800,000 | -23.1% | 100,000 | -44.4% | 1.08% | -32.1% |
| Q4 2016 | $3,643,000 | – | 180,000 | – | 1.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |